- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Piramal Pharma Ltd (PIRM)
Piramal Pharma Ltd stock price live, this page displays NSE PIRM stock exchange data. View the PIRM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Piramal Pharma Ltd real time stock price chart below.
What Is the Piramal Pharma Ltd Stock Price Today?
The Piramal Pharma Ltd stock price today is 237.76.
What Is the Stock Symbol for Piramal Pharma Ltd?
The stock symbol for Piramal Pharma Ltd is "PIRM."
What Stock Exchange Does Piramal Pharma Ltd Trade On?
Piramal Pharma Ltd is listed and trades on the NSE stock exchange.
Is Piramal Pharma Ltd a Good Stock to Buy?
Determining whether Piramal Pharma Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PIRM quote. (ISIN: INE0DK501011)
What Is the Piramal Pharma Ltd Stock Price Today?
The Piramal Pharma Ltd stock price today is 237.76.
What Is the Stock Symbol for Piramal Pharma Ltd?
The stock symbol for Piramal Pharma Ltd is "PIRM."
What Stock Exchange Does Piramal Pharma Ltd Trade On?
Piramal Pharma Ltd is listed and trades on the NSE stock exchange.
Is Piramal Pharma Ltd a Good Stock to Buy?
Determining whether Piramal Pharma Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PIRM quote. (ISIN: INE0DK501011)
237.76
+4.07(+1.74%)
Closed·
Fair Value
An estimate of a Piramal Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
231.33
239.00
52 wk Range
132.30
243.20
PPLPHARMA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Piramal Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
231.33239.00
52 wk Range
132.30243.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PPLPHARMA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Piramal Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
262.91
Upside
+10.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Piramal Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Piramal Pharma acquires majority stake in Yapan Bio for $7.95M- Investing.com
Pro
- Piramal Pharma acquires majority stake in Yapan Bio for $7.95M
- Investing.com
Pro 
Piramal Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 262.91
(+10.58% Upside)
Piramal Pharma Ltd Earnings Call Summary for Q2/2027
- Q2 revenue rose 28% YoY to INR 2,617 crores; EBITDA surged 72% to INR 385 crores with 350+ bps margin expansion, driving shares up 14%.
- Management raised FY2027 revenue growth guidance to 19-20% from mid-teens, citing strong CDMO order momentum and seasonally stronger H2.
- CDMO business led growth at 36% YoY, driven by ADC work, on-patent manufacturing, and multi-geography strategy validation in North America.
- Net debt-to-EBITDA improved to 3.4x from 3.7x; consumer healthcare targets double-digit OTC margins by FY2030 through premiumization.
- Regulatory observations at Morpeth facility and Kenalog supply transition remain key risks; Bayer distribution agreement expires December 2026.
Last Updated: 28/10/2026, 07:02
Read Full TranscriptEarnings
Latest Release
Oct 27, 2026
EPS / Forecast
-- / -0.38
Revenue / Forecast
26.17B / 23.46B
Compare PPLPHARMA to Peers and Sector
Metrics to compare | PPLPHARMA | Peers Peers - average of corresponding metrics from companies closely matching PPLPHARMA: ONESOURCE, LAURUSLABS, DCAL, SAILIFE, MANKIND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPPLPHARMAPeersSector |
|---|---|---|---|---|
P/E Ratio | −151.1x | 39.0x | −0.2x | |
PEG Ratio | 0.20 | 0.99 | 0.00 | |
Price/Book | 3.9x | 4.0x | 2.6x | |
Price / LTM Sales | 3.2x | 4.6x | 2.8x | |
Upside (Analyst Target) | 10.6% | 5.3% | 62.7% | |
Fair Value Upside | Unlock | 2.6% | 8.0% | Unlock |
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids’ wellness, digestives, and women’s health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Piramal Pharma (PPLPHARMA) Stock Price Today?
The Piramal Pharma stock price today is 237.76 INR.
What Stock Exchange Does Piramal Pharma Trade On?
Piramal Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Piramal Pharma?
The stock symbol for Piramal Pharma is "PPLPHARMA."
What Is the Piramal Pharma Market Cap?
As of today, Piramal Pharma market cap is 316.05B INR.
What Is Piramal Pharma's Earnings Per Share (TTM)?
The Piramal Pharma EPS (TTM) is -1.57.
When Is the Next Piramal Pharma Earnings Date?
Piramal Pharma will release its next earnings report on Feb 02, 2027.
From a Technical Analysis Perspective, Is PPLPHARMA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Piramal Pharma Stock Split?
Piramal Pharma has split 0 times.
How Many Employees Does Piramal Pharma Have?
Piramal Pharma has 7120 employees.
What is the current trading status of Piramal Pharma (PPLPHARMA)?
As of Nov 05, 2026, Piramal Pharma (PPLPHARMA) is trading at a price of 237.76 INR, with a previous close of 237.76 INR. The stock has fluctuated within a day range of 231.33 INR to 239.00 INR, while its 52-week range spans from 132.30 INR to 243.20 INR.
What Is Piramal Pharma (PPLPHARMA) Price Target According to Analysts?
The average 12-month price target for Piramal Pharma is 262.91 INR, with a high estimate of 300 INR and a low estimate of 220 INR. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +10.58% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.